Prime Medicine (NASDAQ:PRME – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright‘s price target would suggest a potential upside of 87.35% from the stock’s current price.
PRME has been the subject of several other reports. Jefferies Financial Group reiterated a “market outperform” rating on shares of Prime Medicine in a research report on Monday, September 28th. BMO Capital Markets started coverage on Prime Medicine in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 target price on the stock. Citigroup restated a “market outperform” rating on shares of Prime Medicine in a research report on Friday, September 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prime Medicine in a research note on Monday, August 31st. Finally, Wall Street Zen upgraded Prime Medicine from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.86.
Check Out Our Latest Stock Analysis on PRME
Prime Medicine Price Performance
Prime Medicine stock opened at $4.27 on Monday. The firm has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $3.51. Prime Medicine has a 1-year low of $2.67 and a 1-year high of $5.91. The stock has a market cap of $774.49 million, a price-to-earnings ratio of -4.45 and a beta of 2.13.
Prime Medicine (NASDAQ:PRME – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $4.21 million during the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. Equities analysts expect that Prime Medicine will post -0.97 earnings per share for the current fiscal year.
Institutional Trading of Prime Medicine
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRME. Marshall Wace LLP lifted its stake in Prime Medicine by 225.7% during the third quarter. Marshall Wace LLP now owns 706,281 shares of the company’s stock worth $2,161,000 after purchasing an additional 489,440 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of Prime Medicine during the third quarter worth $150,000. Palumbo Wealth Management LLC boosted its position in shares of Prime Medicine by 52.2% during the third quarter. Palumbo Wealth Management LLC now owns 157,962 shares of the company’s stock worth $483,000 after buying an additional 54,161 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Prime Medicine by 244.2% in the third quarter. Russell Investments Group Ltd. now owns 175,500 shares of the company’s stock valued at $536,000 after buying an additional 124,506 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. acquired a new stake in shares of Prime Medicine in the third quarter valued at $350,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.
About Prime Medicine
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
See Also
- Five stocks we like better than Prime Medicine
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
